Min-Han Tan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2703185/publications.pdf

Version: 2024-02-01

88 papers	8,346 citations	101543 36 h-index	56724 83 g-index
91 all docs	91 docs citations	91 times ranked	13401 citing authors

#	Article	IF	Citations
1	Patterns of somatic mutation in human cancer genomes. Nature, 2007, 446, 153-158.	27.8	2,802
2	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	10.7	808
3	Lifetime Cancer Risks in Individuals with Germline PTEN Mutations. Clinical Cancer Research, 2012, 18, 400-407.	7.0	738
4	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma. Cancer Cell, 2011, 20, 511-523.	16.8	347
5	A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 Probands. American Journal of Human Genetics, 2011, 88, 42-56.	6.2	332
6	A Molecular Classification of Papillary Renal Cell Carcinoma. Cancer Research, 2005, 65, 5628-5637.	0.9	226
7	Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma. Clinical Cancer Research, 2004, 10, 6629-6637.	7.0	223
8	Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of Clinical Pathology, 2012, 65, 69-76.	2.0	220
9	Metastatic nonâ€“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	4.1	189
10	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Journal of Medical Genetics, 2011, 48, 226-234.	3.2	116
11	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	10.7	112
12	Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy. Scientific Reports, 2016, 6, 13.	3.3	97
13	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.9	96
14	Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectives. Biomicrofluidics, 2013, 7, 11810.	2.4	96
15	Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leukemia and Lymphoma, 2008, 49, 462-469.	1.3	95
16	Tumor-derived circulating endothelial cell clusters in colorectal cancer. Science Translational Medicine, 2016, 8, 345ra89.	12.4	92
17	Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer, 2010, 10, 196.	2.6	86
18	Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochemical and Biophysical Research Communications, 2006, 350, 17-24.	2.1	84

#	Article	IF	Citations
19	Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications. Clinical Cancer Research, 2007, 13, 161-169.	7.0	81
20	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	4.1	74
21	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	1.9	71
22	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	1.9	69
23	Nonâ€invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Molecular Oncology, 2015, 9, 850-860.	4.6	59
24	Somatic Pairing of Chromosome 19 in Renal Oncocytoma Is Associated with Deregulated ELGN2-Mediated Oxygen-Sensing Response. PLoS Genetics, 2008, 4, e1000176.	3.5	58
25	Clinical utility of Epsteinâ€Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Communications, 2020, 40, 564-585.	9.2	49
26	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	3.6	47
27	Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma. Scientific Reports, 2017, 7, 7342.	3.3	46
28	The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0118658.	2.5	46
29	Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Research and Treatment, 2012, 131, 849-858.	2.5	45
30	Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells inÂvitro and inÂvivo. Biomaterials, 2014, 35, 9177-9186.	11.4	44
31	Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Npj Genomic Medicine, 2016, 1, 15003.	3.8	44
32	Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer, 2013, 119, 313-324.	4.1	43
33	Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation. Chinese Journal of Cancer, 2016, 35, 10.	4.9	43
34	The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer, 2011, 117, 5314-5324.	4.1	42
35	Gene Expression Profiling of Renal Cell Carcinoma: Fig. 1.. Clinical Cancer Research, 2004, 10, 6315S-6321S.	7.0	39
36	Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. Urology, 2010, 75, 1365-1370.e3.	1.0	36

#	Article	IF	Citations
37	Testicular microlithiasis: recent advances in understanding and management. Nature Reviews Urology, 2011, 8, 153-163.	3.8	36
38	Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e482-e491.	10.7	30
39	Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups. Breast Cancer Research and Treatment, 2014, 145, 635-645.	2.5	28
40	Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Letters, 2008, 272, 260-267.	7.2	27
41	Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted Oncology, 2015, 10, 429-437.	3.6	27
42	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	1.9	26
43	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	1.9	25
44	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS ONE, 2015, 10, e0134102.	2.5	25
45	Targeted therapy for renal cell carcinoma: The next lap. Journal of Carcinogenesis, 2014, 13, 3.	2.5	24
46	A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition. European Urology, 2015, 67, 17-20.	1.9	24
47	Size-Based Enrichment Technologies for Non-cancerous Tumor-Derived Cells in Blood. Trends in Biotechnology, 2018, 36, 511-522.	9.3	24
48	Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. Journal of Clinical Pathology, 2014, 67, 748-750.	2.0	23
49	8q24 and 17q Prostate cancer susceptibility loci in a multiethnic Asian cohort. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1553-1560.	1.6	21
50	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry inÂSingapore. Clinical Genitourinary Cancer, 2015, 13, e285-e295.	1.9	21
51	CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. Modern Pathology, 2015, 28, 352-358.	5.5	21
52	Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC). Familial Cancer, 2014, 13, 281-289.	1.9	20
53	Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese. Oncotarget, 2018, 9, 12796-12804.	1.8	19
54	Reproductive factors and lung cancer risk among women in the Singapore Breast Cancer Screening Project. Lung Cancer, 2015, 90, 499-508.	2.0	18

#	Article	IF	Citations
55	An association between transient hypokalemia and severe acute oxaliplatin-related toxicity predominantly in women. Acta OncolÃ³gica, 2010, 49, 515-517.	1.8	17
56	Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemotherapy and Pharmacology, 2014, 73, 381-388.	2.3	16
57	Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. PLoS ONE, 2015, 10, e0134408.	2.5	15
58	Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 168-175.	1.9	15
59	Gastrointestinal stromal tumour in the elderly. Critical Reviews in Oncology/Hematology, 2009, 70, 256-261.	4.4	14
60	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. Anticancer Research, 2015, 35, 6639-53.	1.1	14
61	Predictive models for the practical management of renal cell carcinoma. Nature Reviews Urology, 2012, 9, 73-84.	3.8	13
62	Identification of Novel Breast Cancer Risk Loci. Cancer Research, 2017, 77, 5428-5437.	0.9	12
63	Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification. Chinese Journal of Cancer, 2011, 30, 144-148.	4.9	12
64	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	1.9	10
65	RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. Journal of the National Cancer Institute, 2014, 106, dju130.	6.3	9
66	Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients. Chinese Journal of Cancer, 2011, 30, 772-778.	4.9	9
67	Assessment of PARP4 as a candidate breast cancer susceptibility gene. Breast Cancer Research and Treatment, 2019, 177, 145-153.	2.5	8
68	Differential radiologic characteristics of renal tumours on multiphasic computed tomography. Singapore Medical Journal, 2017, 58, 262-266.	0.6	8
69	A unique case of spontaneous regression of metastatic papillary renal cell carcinoma: a case report. Cases Journal, 2009, 2, 7769.	0.4	6
70	Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. Journal of Medical Case Reports, 2010, 4, 36.	0.8	6
71	Clinical and molecular characteristics of East Asian patients with von Hippelâ€“Lindau syndrome. Chinese Journal of Cancer, 2016, 35, 79.	4.9	6
72	Gene expression profiling of renal cell carcinoma and clinical implications. Urology, 2005, 65, 231-237.	1.0	5

#	Article	IF	Citations
73	'Prechronous' metastasis in clear cell renal cell carcinoma: a case report. Journal of Medical Case Reports, 2011, 5, 181.	0.8	3
74	Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights. European Urology, 2016, 69, 457-459.	1.9	3
75	Race to Report: Are Vascular Endothelial Growth Factor Genetic Polymorphisms Associated With Outcome in Advanced Breast Cancer Patients Treated With Paclitaxel Plus Bevacizumab?. Journal of Clinical Oncology, 2009, 27, 1342-1342.	1.6	2
76	Papillary renal cell carcinoma with metastatic laparoscopic port site and vaginal involvement: a case report. Journal of Medical Case Reports, 2011, 5, 131.	0.8	2
77	Post-encephalitic segmental dystonia with apraxia of eyelid opening. Parkinsonism and Related Disorders, 2004, 10, 173-175.	2.2	1
78	A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. Acta OncolÃ³gica, 2009, 48, 1079-1082.	1.8	1
79	Association Between Being Underweight and Outcomes in Breast Cancer: Alternative Explanations. Journal of Clinical Oncology, 2010, 28, e177-e177.	1.6	1
80	Exploring the Benefits of Early Access to Palliative Care in Advanced Lung Cancer: Living Better, Living Longer, or Both?. Journal of Clinical Oncology, 2012, 30, 2163-2164.	1.6	1
81	Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 181-194.	0.7	1
82	Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.. Journal of Clinical Oncology, 2012, 30, 451-451.	1.6	1
83	The Tao of bao: a randomised controlled trial examining the effect of steamed bun consumption on night-call inpatient course and mortality. Annals of the Academy of Medicine, Singapore, 2008, 37, 255-3.	0.4	1
84	Lifetime Cancer Risks of PTEN Mutation Carriersâ€"Response. Clinical Cancer Research, 2012, 18, 4214-4214.	7.0	0
85	The Issue of Tissue in Molecular Stratification. Oncologist, 2017, 22, 1560-1560.	3.7	0
86	A unique pair of monozygotic twins with concordant clear cell renal cell carcinoma: a case report. Annals of the Academy of Medicine, Singapore, 2010, 39, 61-3.	0.4	0
87	The Singapore Cancer Network (SCAN) Guidelines: A New Beginning. Annals of the Academy of Medicine, Singapore, 2015, 44, 358-9.	0.4	0
88	World Cancer Day. Annals of the Academy of Medicine, Singapore, 2018, 47, 88-89.	0.4	0